96566-25-5
96566-25-5 structure
- Name: Ablukast
- Chemical Name: 6-acetyl-7-[5-(4-acetyl-3-hydroxy-2-propylphenoxy)pentoxy]-3,4-dihydro-2H-chromene-2-carboxylic acid
- CAS Number: 96566-25-5
- Molecular Formula: C28H34O8
- Molecular Weight: 498.56500
- Catalog: Signaling Pathways GPCR/G Protein Leukotriene Receptor
- Create Date: 2018-02-20 08:00:00
- Modify Date: 2025-08-27 10:18:43
-
Ablukast (Ro 23-3544) is a specific and active leukotriene receptor antagonist. Ablukast effectively reduces LTC4- and antigen-induced bronchoconstriction[1][2]. Ablukast is LTD4 receptor antagonist[3].
| Name | 6-acetyl-7-[5-(4-acetyl-3-hydroxy-2-propylphenoxy)pentoxy]-3,4-dihydro-2H-chromene-2-carboxylic acid |
|---|---|
| Synonyms |
rac-6-acetyl-7-<<5-(4-acetyl-3-hydroxy-2-propylphenoxy)pentyl>oxy>-3,4-dihydro-2H-1-benzopyran-2-carboxylic acid
Ablukast 4-dihydro-2H-1-benzopyran-2-carboxylic acid Ablukastum 7-[5-(4-acetyl-3-hydroxy-2-propylphenoxy)-pentyloxy]-6-acetyl-3,4-dihydro-2H-1-benzopyran-2-carboxylic acid 6-acetyl-7-<5-(4-acetyl-3-hydroxy-2-propylphenoxy)pentyloxy>-3,4-dihydro-2H-1-benzopyran-2-carboxylic acid UNII-000TKM5BBQ Ro-23-3544 Ablukast (USAN/INN) Ablukastum [INN-Latin] 7-[5-(4-acetyl-3-hydroxy-2-propylphenoxy)-pentyloxy]-6-acetyl-3 |
| Description | Ablukast (Ro 23-3544) is a specific and active leukotriene receptor antagonist. Ablukast effectively reduces LTC4- and antigen-induced bronchoconstriction[1][2]. Ablukast is LTD4 receptor antagonist[3]. |
|---|---|
| Related Catalog | |
| Target |
LTD4 |
| In Vitro | Ablukast (Ro 23-3544) is tested for its efficacy in modulating dinitrofluorobenzene (DNFB)-induced allergic and croton oil-induced irritant contact dermatitis in mouse ears. Treatment shortly after elicitation of the dermatitis, and for up to 5 days thereafter, was moderately effective in suppressing DNFB-induced ear swelling in a dose-dependent fashion. Daily pre-treatment of the ears for 1 week causes a more marked reduction of DNFB-induced ear swelling during the first 48 h after elicitation[2]. |
| In Vivo | Ablukast (Ro 23-3544) is tested for its efficacy in modulating dinitrofluorobenzene (DNFB)-induced allergic and croton oil-induced irritant contact dermatitis in mouse ears. Treatment shortly after elicitation of the dermatitis, and for up to 5 days thereafter, was moderately effective in suppressing DNFB-induced ear swelling in a dose-dependent fashion. Daily pre-treatment of the ears for 1 week causes a more marked reduction of DNFB-induced ear swelling during the first 48 h after elicitation[2]. Animal Model: Female BALB/c mice[2] Dosage: Concentrations of 0.1 , 0.5 , 1.0 and 5.0 % of Ablukast Administration: Applied to one of the pretreated ears 1 h after elicitation and at 24 h intervals on the following 4 days; three times daily Result: Effectively reduced DNFB-induced ear swelling. |
| References |
| Density | 1.219g/cm3 |
|---|---|
| Boiling Point | 730.8ºC at 760mmHg |
| Molecular Formula | C28H34O8 |
| Molecular Weight | 498.56500 |
| Flash Point | 240.9ºC |
| Exact Mass | 498.22500 |
| PSA | 119.36000 |
| LogP | 5.15620 |
| Index of Refraction | 1.567 |
| Precursor 9 | |
|---|---|
| DownStream 0 | |
![methyl (R,S)-6-acetyl-7-[5-(4-acetyl-3-hydroxy-2-propylphenoxy)pentoxy]-3,4-dihydro-2H-1-benzopyran-2-carboxylate structure](https://image.chemsrc.com/caspic/142/120329-95-5.png)
